Blog / Archives
Rayno Diagnostics and Tools Portfolio: ILMN, NEOG
Life Sciences: Biopharmaceutical Stocks are Hot, Tools and DX are Not We recommended avoiding the Tools/Dx sector several weeks ago as they were lagging biopharmaceutical stocks due to earnings...
Three Small Cap Stocks for a Rebound in January: AMRI,ASTX,SRLS-UPDATE 1/5/12
January Rally on Schedule for Small Cap Biotech Stocks Three Picks we made on December 14: Albany Molecular (AMRI $2.89) Up 16% Astex Pharmaceuticals (ASTX $1.94) Up 19% SeraCare (SRLS $3.00) Up...
Macro News Kills Holiday Buzz: Markets Off 1.6% and More
Rally Hits a Wall at S&P Q4 High of 1265, Down 2% to 1237 You have heard all the compelling reasons to jump into this market: Seasonality is strong from November through May Charts look good...
Rayno Life Science Portfolio: Tools Rally- A, LIFE, ILMN, QGEN
Illumina (ILMN $30.23) shares spiked today on takeover speculation. The shares were whacked in July and the stock is down 52% YTD on an earnings miss with no guidance. Revenue estimates from...
Pure Play Diagnostics Roster: Metrics with Q3 Earnings
No new buys, currently on HOLD list: ABAX, EXAS, NEOG, QDEL, SRLS. Rayno Life Science Tools And Dx Portfolio Update:Immucor Beats 6/20 update | Raygent.com Outperformers YTD: ABAX up 2.9%,CPHD up...
Macro “Risk On”: Life Science Stock Follow Up 3.4%
Rayno Life Science Portfolios Up 3.4% Two big up days this week were driven primarily by high expectations by Central Bank coordination to cut the cost of emergency dollar funding and news from the...
Rayno Life Science Portfolios Run With NASDAQ Up 3.79%
Life Science Stocks Have a Big Day The Rayno Biopharmaceutical Portfolio was up over 3.7% today as all biotechnology stocks pretty much tracked NASDAQ which was up 3.5%. Although we remain cautious...
Gilead (GILD) $11B Deal for Pharmasset (VRUS) Sparks Biotech Stocks
Pharmasset Buyout Brings To Mind M&A Upside for Biotech Stocks: ETF's and Funds Lead the Way Gilead (GILD $35) stepped up with a huge buyout of Pharmasset (VRUS $134.21) driving the stock up 89%...
Caution on Biotechs With Risk Off Situation-UPDATE 1/5/12 Dendreon Soars
Dendreon (DNDN $10.94) soared 44% today on a business update saying Provenge sales for its prostate cancer treatment were better than expected. Fourth quarter gross revenues were $82M with full year...
Fidelity Biotech Fund (FBIOX) up 7.9% YTD Outperforms Major ETFs
Managed Healthcare Mutual Funds Starting To OutPerform ETFs Earlier this year we wrote an article on Investor Uprising comparing returns on biotech funds and major ETFs. At the time ETF's were...